<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="5658">
  <stage>Registered</stage>
  <submitdate>8/08/2013</submitdate>
  <approvaldate>8/08/2013</approvaldate>
  <nctid>NCT01920633</nctid>
  <trial_identification>
    <studytitle>A Screening Protocol to Assess Adults and Adolescents With Down Syndrome for Eligibility For Upcoming Study of RG1662 (Study BP27832)</studytitle>
    <scientifictitle>A Screening Protocol to Assess Adult and Adolescent Individuals With Down Syndrome for Eligibility to Participate in an Upcoming Study to Evaluate the Efficacy, Safety and Tolerability of RG1662 (Study BP27832)</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>2013-001264-33</secondaryid>
    <secondaryid>BP28947</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Down Syndrome</healthcondition>
    <conditioncode>
      <conditioncode1>Other</conditioncode1>
      <conditioncode2>Research that is not of generic health relevance and not applicable to specific health categories listed above</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Human Genetics and Inherited Disorders</conditioncode1>
      <conditioncode2>Down's syndrome</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>People with Down syndrome - 

</interventions>
    <comparator />
    <control />
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Identification of people with Down syndrome aged 12-30 eligible for upcoming BP27832 study of RG1662</outcome>
      <timepoint>1 day</timepoint>
    </primaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Study participants will be assessed on the following criteria that they will be required to
        meet in order to participate in the future Phase II study BP27832:

          -  Males and females 12-30 years of age (18-30 in the US)

          -  Clinical diagnosis of Down syndrome (trisomy 21) documented by chromosomal analysis
             (karyotyping)

          -  Body-mass Index (BMI) 18-42 and 15-32 kg/m2 inclusive for adults and adolescents
             respectively

          -  Ability to complete the Clinical Evaluation of Language Fundamentals (CELF)-preschool
             2 word classes task (i.e., = 7 for the adults or = 4 for the adolescents in the
             expressive raw score).

          -  Study participant willing and assenting or consenting to participate

          -  Parent or guardian willing to give written informed consent

          -  Study participants must have a parent, or other reliable caregiver who will agree to
             accompany the study participant to clinic visits during the treatment study, BP27832

          -  The parent or caregiver must be a constant and reliable informant with sufficient
             contact with the study participant to have detailed knowledge of the study
             participant's adaptive functioning in order to be able to complete assessments
             accurately

          -  Study participants must be verbal and able to be understood most of the time and must
             not use other forms of communication, signs, symbol boards or devices as their primary
             form of communication

          -  Study participants must have sufficient vision and hearing to participate in study
             evaluations

          -  Study participants on anti-epileptic treatment must be on stable doses for 4 weeks
             prior to enrollment in the treatment protocol</inclusivecriteria>
    <inclusiveminage>12</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>30</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>In the future Phase II study, study participants must not meet any of the following
        criteria :

          -  Study participants with severe lactose intolerance

          -  Study participants with moderate or severe Obstructive Sleep Apnea (OSA) as defined by
             Apnea-Hypopnea Index (AHI) (&gt;15 events per hour not well controlled by positive airway
             pressure therapy with stable settings) for 6 weeks prior to the screening visit

          -  Study participants with history of malignancy if not considered likely to be cured

          -  Personal history of infantile spasms, of epilepsy, of severe head trauma or Central
             Nervous System (CNS) infections (e.g. meningitis), with the exception of a single
             isolated febrile seizure

          -  Study participants with history of epilepsy within the last 2 years.

          -  Evidence of active, clinically significant, and unstable gastrointestinal, renal,
             hepatic, endocrine or cardiovascular system disease

          -  Study participants with a current Diagnostic and Statistical Manual of Mental
             Disorders (DSM-5) diagnosis of any primary psychiatric diagnosis (including autism
             spectrum disorder). Diagnoses that are secondary, such as intellectual disability,
             attention deficit hyperactivity disorder, depression and conduct disorder are allowed
             as long as they are considered stable and to not interfere with conduct of a future
             treatment study

          -  Study participants with a history of suicide attempt or deliberate self-harm due to
             suicidal ideation will not be included. Suicidal ideation (even in the absence of
             suicide attempt or deliberate self-harm) during the 6 months prior to screening

          -  Concomitant use of excluded approved or unapproved medications

          -  Personal or family history of congenital long QT syndrome

          -  History of hepatitis C or known Human Immunodeficiency Virus (HIV) infection

          -  Pregnant or breast feeding</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Observational</studytype>
    <purpose />
    <allocation />
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing>Prospective</timing>
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate />
    <actualstartdate>31/10/2013</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>135</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>31/01/2015</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry />
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Georgia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Illinois</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Maryland</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Massachusetts</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>North Carolina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Texas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Utah</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Wisconsin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Argentina</country>
      <state>Capital Federal</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Argentina</country>
      <state>Ciudad Autonoma de Bs As</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Nova Scotia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Mexico</country>
      <state>Jalisco</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Mexico</country>
      <state>Aguascalientes</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Mexico</country>
      <state>Queretaro</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Auckland</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Dunedin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Wellington</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Singapore</country>
      <state>Singapore</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Girona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Barcelona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Madrid</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Hoffmann-La Roche</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>This is a single visit study in which people with Down syndrome aged 12-30 will attend the
      clinical center to undergo assessments to evaluate their eligibility for potential enrollment
      in the future BP27832 Phase II clinical study which will evaluate the efficacy, safety and
      tolerability of RG1662. Study participants may withdraw from this study at any time and for
      any reason.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01920633</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Clinical Trials</name>
      <address>Hoffmann-La Roche</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>